[1] Feng ZY,Shen YQ,Wang LY,et al. An oligodeoxynucleotide with promising modulation activity for the proliferation and activation of osteoblast [J]. International Journal of Molecular Sciences, 2011, 12(4)∶2543-2555 [2] Shen YQ,Feng ZY,Lin CT,et al. An oligodeoxynucleotide that induces differentiation of bone marrow mesenchymal stem cells to osteoblasts in vitro and reduces alveolar bone loss in rats with periodontitis [J]. International Journal of Molecular Sciences, 2012, 13(3)∶2877-2892 [3] Hou X,Shen YQ,Zhang C,et al. A specific oligodeoxynucleotide promotes the differentiation of osteoblasts via ERK and p38 MAPK pathways [J]. International Journal of Molecular Sciences, 2012, 13(7)∶7902-7914 [4] Kim D,Rhee JW,Kwon S,et al. Immunostimulation and anti-DNA antibody production by backbone modified CpG-DNA [J]. Biochem Biophy Res Co, 2008, 397(2)∶362-367 [5] Capaccioli S,Di Pasquale G,Mini E,et al. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum [J]. Biochemical and biophysical research communications, 1993, 197(2)∶818-825 [6] Hanagata N,Zhang HJ,Yamazaki Z. Chitosan-coated boron nitride nanospheres enhance delivery of CpG oligodeoxynucleotides and induction of cytokines [J]. International Journal of Nanomedicine, 2013, 1783-1793 [7] Lochmann D,Jauk E,Zimmer A. Drug delivery of oligonucleotides by peptides [J]. European Journal of Pharmaceutics and Biopharmaceutics,2004,58(2)∶237-251[8] Amélie B,Elias F,Annette G,et al. Liposomes dispersed within a thermosensitive gel:a new dosage form for ocular delivery of oligonucleotides [J]. Pharmaceutical Research, 1998, 15(9)∶1364-1369 [9] Bejjani RA,BenEzra D,Cohen H,et al. Nanoparticles for gene delivery to retinal pigment epithelial cells [J]. Molecular Vision, 2005, 11∶124-132 [10] 王艳波. 新型PEI衍生物材料的合成及在肿瘤基因递送中的应用研究 [D].吉林大学,2014 [11] Klinman DM,Klaschik S,Sato T, et al. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases [J]. Adv Drug Deliv Rev, 2009, 61(3)∶248-255 [12] Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists [J]. Adv Drug Deliv Rev, 2009, 61∶195-204 [13] Zhang YY,Lin A, Zhang C, et al. Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9 [J]. Cancer Immunology,Immunotherapy, 2014, 6(34)∶357-367 [14] Ferreiro MG, Lloyd G, Bodmeier HR. Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides [J]. Pharmaceutical Research, 2002, 19(6)∶755-764 [15] Sameersingh G, Kaley D, Wilson,et al. The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated CpG-ODN [J]. Journal of Drug Targeting, 2008, 16(7-8)∶564-577 [16] Zhu YF,Meng WJ,Hanagata N. Cytosine-phosphodiester-guanine oligodeoxynucleotide (CpG ODN)-capped hollow mesoporous silica particles for enzyme-triggered drug delivery [J]. Dalton Transactions, 2011, 40(39)∶10203-10208 |